<DOC>
	<DOCNO>NCT00426218</DOCNO>
	<brief_summary>This study multi-center , open label , repeat dose , range find study evaluate safety , tolerability , immunogenicity , pharmacokinetics efficacy ACZ885 , fully human anti-interleukin-1B ( anti-IL-1B ) monoclonal antibody , give subcutaneously pediatric subject active SJIA .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics Subcutaneous ACZ885 Patients With Systemic Juvenile Idiopathic Arthritis ( SJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Male female subject age 4 20 year Female subject childbearing potential may participate negative pregnancy test screen prior dosing , willing use , adequate age , effective method contraception ( e.g . birth control pill , abstinence , doublebarrier contraception , etc . ) study ( date screening ) least 3 month follow last dose . Patient meet diagnostic criterion SJIA , least 6 month disease duration active disease time enrollment define follow : At least 2 joint active arthritis ( use ACR definition active joint ) Spiking , intermittent fever ( body temperature &gt; 38°C several hour day ) CRP &gt; 50 mg/L ( normal range &lt; 10 mg/L ) . Patients take Anakinra , discontinue fail anakinra ( accord physician 's decision ) willing discontinue anakinra use close monitoring ( run phase ) relapse ( reappearance fever and/or CRP increase ) . Willing discontinue second line agent diseasemodifying immunosuppressive drug , include methotrexate corticosteroid . Body weight least 12 kg . Use : Etanercept four week prior Baseline visit Adalimumab eight week prior Baseline visit Infliximab eight week prior Baseline visit Any investigational biologics eight week prior Baseline visit Leflunomide four week prior Baseline visit . Documentation completion full cholestyramine elimination procedure recent leflunomide use require Thalidomide four week prior baseline visit Growth hormone four week prior baseline visit Cyclosporine four week prior Baseline visit Sulfasalazine hydroxychloroquine eight week prior Baseline visit i.v . immunoglobulin ( i.v . Ig ) eight week prior Baseline visit 6Merceptopurine , azathioprine , cyclophosphamide , chlorambucil , 24 week prior Baseline visit Washout period may longer accord local requirement . History recurrent bacterial , fungal viral infection . Evidence currently active bacterial , fungal viral infection . Administration live attenuate vaccine 3 month prior screen visit . Uncontrolled severe systemic symptom and/or biologic feature Macrophage Activation Syndrome ( hemorrhage , central nervous system dysfunction , hepatomegaly , serum fibrinogen level &lt; 2.5 g/L , cytopenia , hypertriglyceridemia , decrease platelet count , increase aspartate transaminase , hyperferritinemia ) ( Ravelli , et al 2005 ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Systemic Juvenile Idiopathic Arthritis</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Anti-IL-1ß Monoclonal Antibody</keyword>
	<keyword>ACZ885</keyword>
	<keyword>SJIA</keyword>
	<keyword>Pediatrics</keyword>
</DOC>